Pulse Biosciences (PLSE) Projected to Post Quarterly Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Pulse Biosciences to post earnings of ($0.31) per share and revenue of $0.5330 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.25 million. On average, analysts expect Pulse Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulse Biosciences Trading Down 3.4%

Shares of PLSE stock opened at $34.25 on Thursday. The business’s fifty day simple moving average is $27.27 and its 200-day simple moving average is $22.55. The company has a market cap of $2.37 billion, a PE ratio of -31.14 and a beta of 1.65. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $36.79.

Insider Buying and Selling

In related news, Director Robert W. Duggan acquired 660,233 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the purchase, the director owned 48,211,433 shares of the company’s stock, valued at approximately $949,283,115.77. This represents a 1.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul A. Laviolette acquired 15,000 shares of the stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $19.69 per share, with a total value of $295,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at approximately $295,350. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. Bank of America Corp DE lifted its position in Pulse Biosciences by 2.7% during the 3rd quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock worth $14,248,000 after acquiring an additional 21,424 shares during the period. State Street Corp increased its holdings in shares of Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after purchasing an additional 25,187 shares during the period. Brooklyn Investment Group increased its holdings in shares of Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares during the period. Portolan Capital Management LLC purchased a new position in shares of Pulse Biosciences in the third quarter worth about $1,809,000. Finally, UBS Group AG raised its stake in shares of Pulse Biosciences by 53.4% in the third quarter. UBS Group AG now owns 76,856 shares of the company’s stock worth $1,360,000 after purchasing an additional 26,739 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a research note on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pulse Biosciences presently has an average rating of “Moderate Buy” and an average target price of $32.33.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.